This year has witnessed a renewed sense of energy and commitment in the fight against malaria. As 2018 comes to a close, I’d like to review this year’s milestones, including the Malaria Summit, new advocacy campaigns and research breakthroughs.
The Quinism Foundation, a charity advocating for research into the side effects of antimalarial drugs has been targeted by a ‘sophisticated’ email attack.
The FDA has approved a new drug for the prevention of malaria. ARAKODA™, the brand name for Tafenoquine, will be produced in tablet form and used by those over the age of 18. Its approval presents a milestone after years of research and discovery in the antimalarial field.